AstraZeneca announces Results of AERISTO P-IIIb trial for Bevespi Aerosphere in COPD patients

 AstraZeneca announces Results of AERISTO P-IIIb trial for Bevespi Aerosphere in COPD patients

AstraZeneca announces Results of AERISTO P-IIIb trial for Bevespi Aerosphere in COPD patients

Shots:
  • The AERISTO study recruited 1,119 patients receiving either Bevespi Aerosphere (7.2/4.8µg) BID via pressurized metered-dose inhaler or umeclidinium/vilanterol (62.5/25µg) QD via dry powder inhaler
  • Another P-III PINNACLE study enrolled ~5,000 patients and is performed to test safety and efficacy of Bevespi Aerosphere vs. umeclidinium/vilanterol
  •  Bevespi Aerosphere (glycopyrronium/formoterol fumarate) is approved in the US and Canada for COPD with an expected regulatory decision from EU by H2’18
Click here to read full press release/ article | Ref: AstraZeneca | Image: Forbes

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post